Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology

Clinical article

Restricted access

Object

Low-grade astrocytomas are slow-growing, infiltrative gliomas that over time may progress into more malignant tumors. Various factors have been shown to affect the time to progression and overall survival including age, performance status, tumor size, and the extent of resection. However, more recently it has been suggested that histological subtypes (fibrillary, protoplasmic, and gemistocytic) may impact patient outcome. In this study the authors have performed a large comparative population-based analysis to examine the characteristics and survival of patients with the various subtypes of WHO Grade II astrocytomas.

Methods

Patients diagnosed with fibrillary, protoplasmic, and gemistocytic astrocytomas were identified through the Surveillance, Epidemiology, and End Results (SEER) database. The chi-square test and Student t-test were used to evaluate differences in patient and treatment characteristics between astrocytoma subtypes. Kaplan-Meier analysis was used to assess overall survival, and the log-rank test was used to evaluate the differences between survival curves. Univariate and multivariate analyses were also performed to determine the effect of various patient, tumor, and treatment variables on overall survival.

Results

A total of 500 cases were included in the analysis, consisting of 326 fibrillary (65.2%), 29 protoplasmic (5.8%), and 145 gemistocytic (29%) variants. Gemistocytic astrocytomas presented at a significantly older age than the fibrillary variant (46.8 vs 37.7 years, p < 0.0001), with protoplasmic and fibrillary subtypes having a similar age. Although protoplasmic and fibrillary variants underwent radiotherapy at similar rates, gemistocytic tumors more frequently received radiotherapy (p = 0.0001). Univariate analysis revealed older age, larger tumor size, and the use of radiotherapy to be poor prognostic factors, with resection being associated with improved survival. The gemistocytic subtype (hazard ratio [HR] 1.62 [95% CI 1.27–2.07], p = 0.0001) also resulted in significantly worse survival than fibrillary tumors. Bivariate analyses demonstrated that older age, the use of radiotherapy, and resection significantly influenced median survival. Tumor subtype also affected median survival; patients who harbored gemistocytic tumors experienced less than half the median survival of fibrillary and protoplasmic tumors (38 vs 82 months, p = 0.0003). Multivariate analysis revealed increasing age (HR 1.05 [95% CI 1.04–1.05], p < 0.0001), larger tumor size (HR 1.02 [95% CI 1.01–1.03], p = 0.0002), and the use of resection (HR 0.70 [95% CI 0.52–0.94], p = 0.018) to be independent predictors of survival. Examination of tumor subtype revealed that the gemistocytic variant (HR 1.30 [95% CI 0.98–1.74], p = 0.074) was associated with worse patient survival than fibrillary tumors, although this only approached significance. The protoplasmic subtype did not affect overall survival (p = 0.33).

Conclusions

Gemistocytic tumor histology was associated with worse survival than fibrillary and protoplasmic astrocytomas. As protoplasmic astrocytomas have a survival similar to fibrillary tumors, there may be limited utility to the identification of this rare variant. However, increased attention should be paid to the presence of gemistocytes in low-grade gliomas as this is associated with shorter time to progression, increased malignant transformation, and reduced overall survival.

Abbreviations used in this paper:GFAP = glial fibrillary acidic protein; HR = hazard ratio; LGA = low-grade astrocytoma; SEER = Surveillance, Epidemiology, and End Results.

Article Information

Address correspondence to: Cory Adamson, M.D., Ph.D., M.P.H., M.H.Sc., Division of Neurosurgery, DUMC 2624, Durham, North Carolina 27710. email: cory.adamson@duke.edu.

Please include this information when citing this paper: published online May 10, 2013; DOI: 10.3171/2013.4.JNS122329.

© AANS, except where prohibited by US copyright law.

Headings

Figures

  • View in gallery

    Kaplan-Meier survival curves of patients with WHO Grade II astrocytomas showing patients older than 40 years to have worse survival than younger patients.

  • View in gallery

    Kaplan-Meier survival curves of patients with WHO Grade II astrocytomas showing significantly worse survival for elderly patients (> 65 years).

  • View in gallery

    Kaplan-Meier survival curves of patients with WHO Grade II astrocytomas showing patients who received radiotherapy to have worse survival.

  • View in gallery

    Kaplan-Meier survival curves of patients with WHO Grade II astrocytomas showing patients who underwent resection to have better survival than those who only received biopsies.

  • View in gallery

    Kaplan-Meier survival curves of patients with WHO Grade II astrocytomas showing gemistocytic tumors to have significantly worse survival than fibrillary and protoplasmic astrocytomas.

References

1

al-Sarraj SBridges LR: p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9:1431491995

2

Avninder SSharma MCDeb PMehta VSKarak AKMahapatra AK: Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations—a study of 32 cases. J Neurooncol 78:1231272006

3

Chaichana KLMcGirt MJLaterra JOlivi AQuiñones-Hinojosa A: Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. Clinical article. J Neurosurg 112:10172010

4

Chang EFClark AJensen RLBernstein MGuha ACarrabba G: Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg 111:2032102009

5

Chang EFSmith JSChang SMLamborn KRPrados MDButowski N: Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. Clinical article. J Neurosurg 109:8178242008

6

Chozick BSPezzullo JCEpstein MHFinch PW: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35:8318381994

7

Daniels TBBrown PDFelten SJWu WBuckner JCArusell RM: Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 81:2182242011

8

Geranmayeh FScheithauer BWSpitzer CMeyer FBSvensson-Engwall ACGraeber MB: Microglia in gemistocytic astrocytomas. Neurosurgery 60:1591662007

9

Hilton DALove SBarber REllison DSandeman DR: Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42:7247291998

10

Hoshino TWilson BCEllis WG: Gemistocytic astrocytes in gliomas. An autoradiographic study. J Neuropathol Exp Neurol 34:2632811975

11

Ishii NTada MHamou MFJanzer RCMeagher-Villemure KWiestler OD: Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 18:587058781999

12

Jung TYJung SMoon JHKim IYMoon KSJang WY: Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg 113:7527572011

13

Karim ABAfra DCornu PBleehan NSchraub SDe Witte O: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:3163242002

14

Kleihues PSoylemezoglu FSchäuble BScheithauer BWBurger PC: Histopathology, classification, and grading of gliomas. Glia 15:2112211995

15

Kösel SScheithauer BWGraeber MB: Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery 48:1871942001

16

Kraus JABolln CWolf HKNeumann JKindermann DFimmers R: TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10:1431491994

17

Krouwer HGDavis RLSilver PPrados M: Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74:3994061991

18

Lind-Landström THabberstad AHTorp SH: Proliferative activity and histopathological features in diffuse grade II astrocytomas. APMIS 120:6406472012

19

Lote KEgeland THager BStenwig BSkullerud KBerg-Johnsen J: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 15:312931401997

20

Malin JLKahn KLAdams JKwan LLaouri MGanz PA: Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 94:8358442002

21

Okamoto YDi Patre PLBurkhard CHorstmann SJourde BFahey M: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49562004

22

Pignatti Fvan den Bent MCurran DDebruyne CSylvester RTherasse P: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:207620842002

23

Prayson RAEstes ML: Protoplasmic astrocytoma. A clinicopathologic study of 16 tumors. Am J Clin Pathol 103:7057091995

24

Reis RMHara AKleihues POhgaki H: Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathol 102:4224252001

25

Sanai NBerger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:7537642008

26

Sanai NBerger MS: Recent surgical management of gliomas. Adv Exp Med Biol 746:12252012

27

Sanai NChang SBerger MS: Low-grade gliomas in adults. A review. J Neurosurg 115:9489652011

28

Schomas DALaack NNRao RDMeyer FBShaw EGO'Neill BP: Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 11:4374452009

29

Smith JSChang EFLamborn KRChang SMPrados MDCha S: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26:133813452008

30

Tay KLTsui APhal PMDrummond KJTress BM: MR imaging characteristics of protoplasmic astrocytomas. Neuroradiology 53:4054112011

31

Tihan TVohra PBerger MSKeles GE: Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J Neurooncol 76:1751832006

32

van den Bent MJAfra Dde Witte OBen Hassel MSchraub SHoang-Xuan K: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:9859902005

33

Walker DGKaye AH: Low grade glial neoplasms. J Clin Neurosci 10:1132003

34

Watanabe KPeraud AGratas CWakai SKleihues POhgaki H: p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 95:5595641998

35

Watanabe KTachibana OYonekawa YKleihues POhgaki H: Role of gemistocytes in astrocytoma progression. Lab Invest 76:2772841997

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 222 222 69
Full Text Views 469 469 41
PDF Downloads 154 154 10
EPUB Downloads 0 0 0

PubMed

Google Scholar